Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update

01 Mar 2026, 22:38 by Tristan Rich · The Markets Daily

Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) was the recipient of a large increase in short interest in February. As of February 13th, there was short interest totaling 942,054 shares, an increase of 41.8% from the January 29th total of 664,201 shares. Based on an average daily trading volume, of 1,305,670 shares, the short-interest ratio is currently 0.7 days. Approximately 1.5% of the company’s stock are sold short. Approximately 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 1,305,670 shares, the short-interest ratio is currently 0.7 days.

Opus Genetics Trading Up 15.9%

NASDAQ:IRD traded up $0.57 during trading hours on Friday, reaching $4.16. 1,227,926 shares of the stock were exchanged, compared to its average volume of 1,077,028. The business has a 50-day moving average of $2.65 and a two-hundred day moving average of $2.08. Opus Genetics has a twelve month low of $0.65 and a twelve month high of $4.17. The company has a market capitalization of $286.87 million, a price-to-earnings ratio of -2.21 and a beta of 0.58. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.18.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on IRD shares. Chardan Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Opus Genetics in a research report on Thursday, November 13th. B. Riley Financial began coverage on Opus Genetics in a research note on Wednesday, December 10th. They issued a “buy” rating and a $9.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Opus Genetics in a report on Wednesday, January 28th. Piper Sandler started coverage on Opus Genetics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, Lifesci Capital upgraded shares of Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Opus Genetics currently has an average rating of “Buy” and an average price target of $7.75.

Get Our Latest Analysis on Opus Genetics

Insider Activity at Opus Genetics

In other Opus Genetics news, Director Cam Gallagher bought 83,000 shares of Opus Genetics stock in a transaction on Monday, December 29th. The stock was acquired at an average cost of $1.97 per share, with a total value of $163,510.00. Following the completion of the acquisition, the director owned 83,000 shares in the company, valued at approximately $163,510. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Fighting Blindness Foundation sold 4,000,000 shares of Opus Genetics stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the transaction, the director owned 5,492,171 shares in the company, valued at approximately $11,808,167.65. This trade represents a 42.14% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

Hedge funds have recently added to or reduced their stakes in the stock. Comerica Bank purchased a new stake in Opus Genetics during the 1st quarter valued at approximately $29,000. Royal Bank of Canada acquired a new stake in shares of Opus Genetics in the 1st quarter worth approximately $299,000. BIOS Capital Management LP raised its holdings in Opus Genetics by 270.1% during the second quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock worth $3,462,000 after purchasing an additional 2,688,180 shares during the last quarter. Voss Capital LP grew its stake in Opus Genetics by 260.8% in the 2nd quarter. Voss Capital LP now owns 541,159 shares of the company’s stock valued at $510,000 after acquiring an additional 391,159 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of Opus Genetics by 6.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company’s stock worth $3,152,000 after purchasing an additional 188,028 shares in the last quarter. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

About Opus Genetics

(Get Free Report)